Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 3/20 | 0.56 |
| ▸ | CSF1R | P07333 | 11/20 | 0.56 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.52 |
| ▸ | SGMS2 | Q8NHU3 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5997052 | 0.87 | CSF1R (0.64) | CYP11B2CSF1RSGMS2 | |
| SCHEMBL5998110 | 0.83 | P4HTM (0.48) | — | |
| SCHEMBL5999675 | 0.79 | LCK (0.57) | CYP11B2SGMS2 | |
| SCHEMBL2495486 | 0.79 | CSF1R (0.51) | CYP11B2CSF1RSGMS2 | |
| SCHEMBL2494867 | 0.79 | CSF1R (0.70) | CSF1R | |
| SCHEMBL2491995 | 0.78 | CSF1R (0.84) | CSF1R | |
| SCHEMBL18160285 | 0.78 | CSF1R (0.74) | CYP11B2CSF1R | |
| SCHEMBL5814463 | 0.76 | CSF1R (0.70) | CYP11B2CSF1RKCNMA1 | |
| SCHEMBL3930125 | 0.75 | CYP11B2 (0.68) | CYP11B2CSF1RKCNMA1 | |
| SCHEMBL12190166 | 0.75 | CYP11B2 (0.63) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | CYP11B2 4444/4885CSF1R 758/4885KCNMA1 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.